Latest news with #DigitalHealth
Associated Press
2 days ago
- Health
- Associated Press
Hong Kong Baptist University and Elsevier Report Highlights Global Expansion of Chinese Medicine Research, Urges Standardised Frameworks for Broader Integration
ISTANBUL, TURKEY - Media OutReach Newswire - 18 June 2025 – The report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine' released today by Hong Kong Baptist University (HKBU) and Elsevier, reveals the growing impact of Chinese Medicine research on global healthcare and modern health challenges. In this context, 'Chinese Medicine research' encompasses not only clinical practice, but also basic and translational science, AI-driven systems medicine, and the network pharmacology of herbal formulas. This first bibliometric analysis of Chinese Medicine research from 2014 to 2023 highlights the field's rapid growth, interdisciplinarity, and societal impact on Digital Health and Systems Medicine. HKBU and Elsevier launched a new report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine', highlighting the growing global impact of Chinese Medicine research in diversified healthcare solutions. Key findings from the report include: Bridging a global integration gap Chinese Medicine's mainstream integration lacks a global, transparent, evidence-based framework. To elevate its scientific profile, key strategies include developing internationally accepted clinical guidelines through expert consensus, enhancing trial reporting standards to improve research quality, and fostering interdisciplinary, cross-regional collaboration to drive innovation and systemic impact. ''Evolving Legacy' demonstrates how Chinese Medicine research has matured into a global, evidence-informed field,' said Professor Lyu Aiping, Vice-President (Research & Development), HKBU, and a leading expert in Chinese Medicine. 'We envision a future where data science and AI illuminate what Chinese Medicine research has long intimated, providing deeper insights into health classifications and compound interventions. The next frontier is using Chinese Medicine research to uncover insights possibly overlooked in Digital Health and Systems Medicine, strengthening their scientific foundation and impact.' 'This report offers unprecedented insights into Chinese Medicine's evolving scientific landscape,' added Basak Candemir, Business Development Director, Analytical and Data Services, Elsevier. 'It illuminates the growing global impact of Chinese Medicine research and its role in diversified healthcare solutions, making a vital step towards bridging traditional knowledge with modern validation for the benefit of global health.' The report was developed using Elsevier's bibliometric tools, Scopus and SciVal, based on a comprehensive dataset and case studies compiled in collaboration with HKBU Chinese Medicine research experts. The report can be accessed on Hashtag: #HKBU The issuer is solely responsible for the content of this announcement.
Associated Press
3 days ago
- Health
- Associated Press
Hong Kong Baptist University and Elsevier Report Charts Global Growth of Chinese Medicine Research, Calls for Standardised Frameworks for Broader Integration
ISTANBUL, TURKEY - Media OutReach Newswire - 17 June 2025 – The report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine' released today by Hong Kong Baptist University (HKBU) and Elsevier, reveals the growing impact of Chinese Medicine research on global healthcare and modern health challenges. In this context, 'Chinese Medicine research' encompasses not only clinical practice, but also basic and translational science, AI-driven systems medicine, and the network pharmacology of herbal formulas. This first bibliometric analysis of Chinese Medicine research from 2014 to 2023 highlights the field's rapid growth, interdisciplinarity, and societal impact on Digital Health and Systems Medicine. HKBU and Elsevier launched a new report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine', highlighting the growing global impact of Chinese Medicine research in diversified healthcare solutions. Key findings from the report include: Bridging a global integration gap Chinese Medicine's mainstream integration lacks a global, transparent, evidence-based framework. To elevate its scientific profile, key strategies include developing internationally accepted clinical guidelines through expert consensus, enhancing trial reporting standards to improve research quality, and fostering interdisciplinary, cross-regional collaboration to drive innovation and systemic impact. ''Evolving Legacy' demonstrates how Chinese Medicine research has matured into a global, evidence-informed field,' said Professor Lyu Aiping, Vice-President (Research & Development), HKBU, and a leading expert in Chinese Medicine. 'We envision a future where data science and AI illuminate what Chinese Medicine research has long intimated, providing deeper insights into health classifications and compound interventions. The next frontier is using Chinese Medicine research to uncover insights possibly overlooked in Digital Health and Systems Medicine, strengthening their scientific foundation and impact.' 'This report offers unprecedented insights into Chinese Medicine's evolving scientific landscape,' added Basak Candemir, Business Development Director, Analytical and Data Services, Elsevier. 'It illuminates the growing global impact of Chinese Medicine research and its role in diversified healthcare solutions, making a vital step towards bridging traditional knowledge with modern validation for the benefit of global health.' The report was developed using Elsevier's bibliometric tools, Scopus and SciVal, based on a comprehensive dataset and case studies compiled in collaboration with HKBU Chinese Medicine research experts. The report can be accessed on Hashtag: #HKBU The issuer is solely responsible for the content of this announcement.
Phone Arena
4 days ago
- Health
- Phone Arena
Samsung announces Galaxy Watch upgrades for better sleep, fitness, and recovery
Samsung has just announced new health features for the upcoming Galaxy Watch (which should be the Galaxy Watch 8 series, although the company doesn't specifically say it) aimed at further improving your health and daily habits for a healthier lifestyle overall. The new features are aimed at improving sleep, heart health, fitness, and nutrition. Here are the new features Samsung has announced today: Bedtime Guidance: for optimizing your sleep habits Vascular Load: measuring stress on your vascular system when you sleep Running Coach: strategizing your training Antioxidant Index: measuring carotenoids for healthy aging With these new features, Samsung aims to help you become healthier by motivating you through instant feedback, providing rewards for successes or indicating warning signs. -Dr. Hon Pak, Senior Vice President and Head of Digital Health Team, Mobile eXperience, Samsung Electronics. Dr. Pak also says that the new insights should lead to meaningful changes in users' lives and health management. Now, let's see exactly how these features work. Image Credit - Samsung Thanks to this feature, your Galaxy Watch will now suggest an optimal bedtime for you. This will be based on your lifestyle and sleep patterns, and your timepiece will also send you reminders to help you stick to a healthier bedtime routine. The feature works by analyzing your past three days' sleep patterns and evaluating your need for sleep pressure and your circadian rhythm. The suggested bedtime should maximize your alertness the next day. You may find this especially useful if you're trying to optimize your sleep after a period of irregular sleep (I find myself in this situation way too often for my own good). This is also super helpful if you have inconsistent sleep schedules between weekdays and weekends (yours truly is also guilty of that). All these factors will be taken into account by the feature, so the suggested bedtime should offer you an adequate amount of sleep. Image Credit - Samsung The Galaxy Watch will measure the amount of stress on your vascular system while you sleep as well. Basically, your vascular system carries blood throughout the body and delivers oxygen, and nutrients, while removing you sleep, stress on your vascular system should naturally dip. However, Samsung notes, that excessive fluctuations can impact your cardiovascular health and overall wellbeing. The feature will measure your vascular load and provide insights, taking into account sleep, exercise, and stress. Image Credit - Samsung Samsung is seeking to support runners with a new feature that should help you avoid getting injuries. Often, people who run can over-pace themselves, or not optimally push themselves. To help with that, Running Coach will offer you optimized-intensity and injury-preventing training suggestions, which makes it ideal for beginners or people who are not running all the time. The feature offers real-time guidance and motivation, providing you with a tailored training program based on your fitness level and your goals. When you wear your watch, you just need to run for 12 minutes for it to analyze your performance and running level. The smartwatch will then give you a running level from 1 to 10. You will also get a detailed training plan to help you complete a 5K, 10K, half marathon, or full marathon, based on your level. When you complete your training session, you'll also level up and have running challenges. Image Credit - Samsung Last, but not least, we have the Antioxidant Index feature. It is aimed at helping you age healthily. Drinking alcohol, smoking, UV exposure, stress and lack of sleep can accelerate agin of your skin by increasing free radicals in the body. These free radicals accelerate aging. Meanwhile, antioxidants are nutrients that are found in many healthy foods. Those neutralize the free radicals and help prevent illnesses and promote healthy aging. With this new Antioxidant Index, your Galaxy Watch will measure carotenoids (antioxidants found in green and orange veggies and fruit and stored in your skin). The Watch's BioActive sensor is used to measure carotenoids in five seconds. Of course, you'll then have insights that can help you improve your daily habits. For example, if you drink carrot juice, the changes in the carotenoids will show up in the index and act as motivation to make healthier choices. All these features are extremely helpful, especially for people like me who would love to improve their health, sleep, and overall wellbeing, but don't really know where to start. And also, needing lots of motivation. Samsung has announced these features for an 'upcoming Galaxy Watch', which is most likely the Galaxy Watch 8 , expected to be announced alongside the Galaxy Z Fold 7 and Z Flip 7 sometime next month. However, Vascular Load and Antioxidant Indext can also work on the Galaxy Watch Ultra (or later), and the Running Coach feature will be available on Galaxy Watch 7 and later.
Yahoo
29-05-2025
- Business
- Yahoo
Alcohol Use Disorder (AUD) Market Trends and Forecasts (2025-2030) by Drug Class, Treatment Type, End User, Distribution Channel, Formulation, Region and Country
Featuring Profiles of Key Players Alkermes, H. Lundbeck, Teva Pharmaceutical Industries, Viatris, Sandoz International and More Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Alcohol Use Disorder Market by Drug Class, Treatment Type, End User, Distribution Channel, Formulation - Global Forecast to 2030" report has been added to Alcohol Use Disorder Market grew from USD 1.28 billion in 2024 to USD 1.37 billion in 2025. It is expected to continue growing at a CAGR of 6.60%, reaching USD 1.88 billion by landscape of AUD treatment is undergoing transformative shifts that redefine conventional paradigms and unlock new avenues for patient engagement. Digital health solutions, exemplified by teletherapeutic platforms and mobile applications, are enhancing adherence and extending the reach of behavioral interventions. Concurrently, regulatory bodies are recalibrating approval pathways to accommodate novel modalities, from sustained-release injectables to adaptive combination therapies. This convergence of technological innovation and regulatory agility accelerates the translation of research breakthroughs into clinical trends further inform strategic pivots, as rising incidence in younger cohorts compels the design of more personalized, stigma-sensitive outreach programs. Pharmaceutical developers are responding by enhancing patient support services and leveraging real-world evidence to optimize dosing regimens. Meanwhile, payers are reassessing reimbursement frameworks to reward value-based outcomes over volume-driven metrics. Collectively, these shifts signal a more integrated, patient-centric future for AUD management, where therapy personalization and outcome measurement coalesce to improve both clinical efficacy and economic the Ramifications of 2025 United States Tariffs on AUD TherapiesThe imposition of United States tariffs in 2025 has reverberated throughout the global supply chain for AUD therapies, prompting a reassessment of sourcing strategies and cost structures. Raw material levies on key active pharmaceutical ingredients have elevated production expenses, particularly for excipients integral to effervescent and sustained-release formulations. Manufacturers reliant on international chemical suppliers have encountered upward price pressure, resulting in margin compression and, in some cases, temporary repricing at the point of mitigate these effects, several drug producers have expedited domestic procurement agreements and invested in localized manufacturing capabilities. While these measures enhance supply chain resilience, they require significant capital outlays and extended lead times. Payers and providers have also felt the ripple effects, with negotiated contract terms evolving to accommodate incremental cost burdens. Amid these market dynamics, strategic collaboration between pharmaceutical companies and contract manufacturers has emerged as a critical lever to safeguard continuity of supply and protect patient access. The collective response underscores the delicate interplay between trade policy and therapeutic availability in the AUD Dynamics Shaping the AUD MarketRegional dynamics exert a powerful influence on the trajectory of AUD treatments. In the Americas, robust healthcare infrastructure and substantial public funding underpin expansive adoption of both pharmacotherapies and integrated behavioral programs. The United States remains the epicenter of innovation, supported by a comprehensive network of academic research centers and a growing emphasis on telemedicine reimbursement. Latin American markets are witnessing gradual uptake, driven by rising incidence rates and policy initiatives aimed at expanding rural healthcare Europe, Middle East and Africa, market maturity varies widely. Western European nations boast well-established reimbursement frameworks and stringent regulatory processes, fostering incremental innovation in drug delivery and patient support models. In contrast, emerging markets in the Middle East and parts of Africa contend with limited infrastructure and variable regulatory oversight, creating both challenges and opportunities for suppliers willing to invest in capacity-building partnerships and localized Asia-Pacific region presents a dual narrative of rapid urbanization and shifting cultural attitudes toward alcohol use. Markets such as China, India and Australia are allocating increased resources toward AUD screening and treatment integration within primary care settings. Government initiatives aimed at destigmatizing behavioral therapy are gaining momentum, while private sector players explore digital therapeutics to overcome geographic barriers. Collectively, these regional insights underscore the necessity of geographically tailored strategies that align with local regulatory environments, payer structures and patient engagement Landscape and Key Industry PlayersThe competitive landscape of AUD therapeutics features established pharmaceuticals alongside emerging biotechnology innovators. Leading companies have fortified their market positions through strategic product life-cycle management, launching reformulated versions and extended-release alternatives to prolong patent exclusivity. Some firms have executed targeted acquisitions to integrate niche behavioral health capabilities or expand geographic reach, while others have forged co-development agreements to share R&D costs and accelerate pipeline entrants are disrupting traditional paradigms by advancing novel delivery systems and repurposing existing compounds for adjunctive use. Several players are exploring advanced drug-device combinations to optimize dosing adherence, while digital health start-ups collaborate with pharmaceutical sponsors on teletherapy platforms that integrate electronic patient-reported outcomes. Formulary negotiations and patient assistance programs have become critical battlegrounds, with manufacturers deploying real-world evidence and health economics data to secure favorable reimbursement this milieu, companies that demonstrate agility in regulatory navigation, supply chain optimization and stakeholder engagement are poised to gain competitive advantage. The continual interplay between legacy portfolio optimization and next-generation product introductions shapes the contours of market leadership and defines the success metrics for future Imperatives for Industry LeadershipIndustry leaders must adopt proactive strategies that anticipate evolving market demands and regulatory shifts. First, deepening investments in digital health integration will bridge gaps between pharmacotherapy and behavioral interventions, enhancing patient retention and improving long-term outcomes. Deploying advanced analytics to personalize treatment pathways can also heighten efficacy and reduce dropout rates. Second, strengthening partnerships with contract manufacturing organizations can mitigate supply chain disruptions triggered by external trade policies, ensuring consistent product availability across diverse forging alliances with payers and provider networks to design value-based reimbursement models will be essential for demonstrating cost-effectiveness and driving formulary placement. Collaborative real-world evidence initiatives can substantiate clinical and economic benefits, paving the way for risk-sharing agreements. Finally, expanding into underserved and emerging markets requires tailored go-to-market approaches that address local infrastructure constraints and cultural attitudes toward behavioral health. By proactively implementing these imperatives, industry stakeholders can navigate uncertainty and secure sustained growth in the accelerating AUD Segmentation & CoverageThis research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations: Drug Class Acamprosate Effervescent Tablet Oral Tablet Disulfiram Oral Tablet Naltrexone Injectable Oral Tablet Treatment Type Behavioral Therapy Cognitive Behavioral Therapy Family Therapy Motivational Enhancement Therapy Combined Therapy CBT With Pharmacotherapy MET With Pharmacotherapy Pharmacotherapy Injectable Drugs Oral Drugs End User Home Healthcare Home Visits Telehealth Hospitals Private Hospitals Public Hospitals Rehabilitation Centers Inpatient Outpatient Specialty Clinics Alcohol Rehabilitation Clinics Psychiatric Clinics Distribution Channel Hospital Pharmacies Private Hospital Pharmacies Public Hospital Pharmacies Online Pharmacies E-Commerce Websites Mobile Apps Retail Pharmacies Chain Pharmacies Independent Pharmacies Specialty Pharmacies AUD Specialty Pharmacies General Specialty Pharmacies Formulation Dispersible Tablet Effervescent Tablet Injectable Intramuscular Intravenous Subcutaneous Oral Tablet Immediate Release Sustained Release This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions: Americas United States California Texas New York Florida Illinois Pennsylvania Ohio Canada Mexico Brazil Argentina Europe, Middle East & Africa United Kingdom Germany France Russia Italy Spain United Arab Emirates Saudi Arabia South Africa Denmark Netherlands Qatar Finland Sweden Nigeria Egypt Turkey Israel Norway Poland Switzerland Asia-Pacific China India Japan Australia South Korea Indonesia Thailand Philippines Malaysia Singapore Vietnam Taiwan This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies: Alkermes plc H. Lundbeck A/S Teva Pharmaceutical Industries Ltd. Viatris Inc. Sandoz International GmbH Dr. Reddy's Laboratories Ltd. Sun Pharmaceutical Industries Ltd. Aurobindo Pharma Ltd. Lupin Limited Cipla Limited Key Attributes Report Attribute Details No. of Pages 192 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $1.37 Billion Forecasted Market Value (USD) by 2030 $1.88 Billion Compound Annual Growth Rate 6.6% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
28-05-2025
- Business
- Associated Press
Last Call! Global Startups to Get on Board EPIC 2025
Don't Miss Out on the Million-dollar Opportunity at Asia's Most Dynamic Ecosystem HONG KONG SAR - Media OutReach Newswire - 28 May 2025 - The 9th Elevator Pitch International Competition (EPIC 2025), organised by Hong Kong Science and Technology Parks Corporation (HKSTP), has only 3 weeks left for global startups with their anchor in FinTech, and new tech tracks Digital Health and Green Tech, respond to the call to one of Asia's largest innovation arenas. Participants will 60-second pitch their way to business matching and investment opportunities for a lift towards success. Last Call! Global Startups to Get on Board EPIC 2025 Supported by 20 global financial and corporate partners collectively managing an AUM close to US$100B and operating across Asia, Europe and North America, EPIC 2025 offers an unprecedented US$100M targeted funding pool, US$240,000 cash prizes, and an extensive experience for mid- to late-stage startups to grow from regional names to international labels: Key Dates Application Period: Now to 17 June 2025, 23:59 (GMT+8) Online Regional Pitch: July 2025 Finalist Announcement: August 2025 EPIC Week in Hong Kong: 3 – 7 November 2025 Mid- to late-stage startups under 10 years old, focused on Digital Health Tech, FinTech, or GreenTech, and registered as businesses with plans to expand R&D or operations to Hong Kong and/or the Greater Bay Area (GBA), are eligible to enter for EPIC. As the journey moves along, a series of highlights in the week-long EPIC Week will be made available to finalists speeding for the finish line, including Tech Spotlight for a showcase of their innovative solutions exclusive to potential investors and corporate decision-makers, in engaging instant and in-depth conversations; and the Greater Bay Area Exploration for a guided tour of a glimpse into the vast opportunities in the GBA and beyond—where complimentary flight and accommodation sponsored (*T&C applies) for contestants overseas. Albert Wong, CEO of HKSTP said: 'Following the success of EPIC 2024 receiving applause from 47 economies, making it a more impactful event is where we're going this year, as well as more inclusive, which is why we're having new tech tracks, at a new location in Hong Kong, with new formats, yet one thing remains the same—it is an opportunity you don't want to miss.' Global application for EPIC 2025 is opened until 17 June 2025, 23:59 (GMT+8). For details, please visit for more. Hashtag: #HKSTP #EPIC2025 The issuer is solely responsible for the content of this announcement. About Hong Kong Science and Technology Parks Corporation Hong Kong Science and Technology Parks Corporation (HKSTP) is a statutory body leading as one of the world's most dynamic innovation and technology ecosystems, powering through a future with the united force of over 24,000 visionaries working at more than 2,300 tech companies from 25 countries and regions, across multiple locations including Hong Kong Science Park, InnoCentre, Hong Kong Science Park Shenzhen Branch, and the InnoParks. From R&D infrastructure and investment opportunities, to industry networks and talent traction, HKSTP offers comprehensive support that translates innovative ideas to commercialisable solutions. With 13 unicorns and dozens of world-firsts, HKSTP will continue the momentum calling for global innovators to join the community with Keep Up spirits. More information about HSKTP is available at
